Inositol 1,4,5-trisphosphate (InsP3) is a component of the phosphoinositide second-messenger system which mobilizes Ca2" from intracellular stores. Recently, an InsP3 receptor binding protein from rat cerebellar membranes was solubilized and purified to homogeneity. The potent inhibition by Ca2" of [3H]InsP3 binding to the InsP3 receptor in cellular membranes is not apparent in the purified receptor. The Ca2"-dependent inhibition of [3H]InsP3 binding in the crude homogenate (concn. giving 500 inhibition = 300 nM) can be restored by addition of solubilized cerebellar membranes to the purified receptor. In the present study, we further characterize the protein in solubilized membranes which confers Ca2"-sensitivity to the receptor, and which we term 'calmedin'. Calmedin appears to be a neutral membrane protein with an estimated Mr of 300000 by gel filtration in the presence of Triton X-100. Calmedin confers a Ca2"-sensitivity to InsP3 receptor binding, which can be completely reversed by 10 min incubation with EDTA and therefore does not represent Ca2"-dependent proteinase action. Calmedin effects on the purified InsP3 receptor depend on Ca2' binding to the calmedin, although Ca2' also binds directly to the InsP3 receptor. The regional distribution of calmedin differs from that of the InsP3 receptor in the brain, suggesting that it also mediates other Ca2+-dependent functions. Calmedin activity in peripheral tissues is much lower than in brain.
INTRODUCTION
Ca2l is a major mediator of the effects of the phosphoinositide system which serves as a second messenger for numerous neurotransmitters, hormones and growth factors [1] [2] [3] [4] [5] . In the phosphoinositide cycle, phosphatidylinositol 4,5-bisphosphate is converted into diacylglycerol and inositol 1,4,5-trisphosphate (InsP3) after receptor activation [1, 6] . InsP3 appears to bind to receptors on intracellular membranes to release Ca2" [1, 7] . Specific binding sites for InsP3 have been demonstrated in peripheral tissues [8] [9] [10] [11] and in the brain, where sites are highly concentrated in the cerebellum [12, 13] . The InsP3-binding site in the brain is potently inhibited by Ca2" with 50 % inhibition at about 300 nM [13] . We have purified the InsP3-binding site from brain to homogeneity [14] . To date, we have not shown direct evidence for involvement of this binding site in Ca2" release. The purified InsP3-binding site solubilized in Triton X-100 has a native Mr of about 106, whereas on SDS/polyacrylamide-gel electrophoresis its apparent Mr is 260000 [14] . In contrast with the potent inhibition of InsP3 binding to brain membranes by Ca2", InsP3 binding to the purified receptor is unaffected by Ca2" [14] . We have shown that, in the course of purification of the receptor protein, a detergent-solubilized membrane protein which conveys the inhibitory effects of Ca2" was separated from the InsP3 receptor [14] . Inhibition of receptor binding by Ca2+ could be restored by adding detergent-solubilized membrane fractions back to the purified receptor [14] . In the present study we characterize several properties of the protein which mediates the inhibitory effect of Ca2"on the InsP3 receptor, and which we term 'calmedin'.
MATERIALS AND METHODS Materials
[3H]InsP3 (3.6 Ci/mmol) was obtained from NEN/ DuPont. InsP3 was obtained from Amersham. Other reagents were from Sigma or Bio-Rad. Preparation of the InsP3 receptor and heparin flowthrough The InsP3 receptor protein was purified as in our earlier study [14] , with minor modifications. Cerebella from male Sprague-Dawley rats (200-300 g) or bovine cerebella obtained from a local slaughterhouse were homogenized (Polytron setting 9, 10 s) in 50 vol. of icecold buffer A (50 mM-Tris/HCl, pH 7.7, 1 mM-EDTA, 1 mM-fl-mercaptoethanol) and pelleted by centrifugation (35 000 g, 15 min). The supernatants were decanted and the pellets were twice resuspended in 50 vol. of buffer A and centrifuged (35000 g, 15 min). The pellets were resuspended in a final volume of buffer A to give 50 mg original wet wt./ml. Triton X-100 was added to a final concentration of 1 % (v/v) and the membranes were incubated for 30 min at 4 'C. The membranes were centrifuged for 1 h at 48000 g and the supernatant was collected. The solubilized fraction was made 0.25 M in NaCl and then passed over a heparin-agarose column (3 cm x 3 cm) equilibrated with buffer A containing 0.25 M-NaCl and 0.1 % Triton X-100. The membrane Abbreviation used: InsP3, inositol 1,4,5-trisphosphate.
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Vol. 254 component responsible for Ca2" inhibition flowed through the column completely (subsequently designated as 'heparin flow-through'), whereas all InsPJ-binding activity was retained on the column. The column was washed with 5 column vol. of buffer A with 0.25 M-NaCl and 0.1 % Triton X-100, and eluted with buffer A with 0.5 M-NaCl and 0.1 00 Triton X-l00. The eluate was then passed through a concanavalin A column (3 cm x 3 cm), washed with 100 mM-NaCI/50 mM-Tris (pH 7.7)/0.1 00
Triton X-100/1 mM-fl-mercaptoethanol (buffer B), and the purified receptor was eluted with buffer B with 1 Ma-methyl mannopyranoside.
I3HIInsP3 binding to the purified receptor Purified InsP3 receptor (0.1 C4g) solubilized in buffer A containing detergent was incubated with 12.5 nM-[3H]InsP3 and either buffer A or heparin flow-through (containing calmedin activity) in a total volume of 200 u1l. In experiments with Ca2", 1.7 mM-CaCl2 (final free [Ca2"] = 700 gM) was added and the mixture incubated for 1 min (or for a specified time) at 4°C, and then loaded on a 1 ml column packed with 70 g of Bio-Gel P-10 resin/l and centrifuged at 1000 g for 6 min. Liquid-scintillation cocktail (5 ml) was added to the void volume of these columns, and radioactivity was determined.
[3H]InsP3 binding was linear with purified InsP3-receptor concentration, and not more than 10% of the radioactivity added was bound. All of the radioactivity could be displaced by 1 pM-InsP3.
Assessment of calmedin activity
[3H]InsP3 binding was assayed as described above.
Parallel determinations were made (a) in the absence of Ca2", (b) in the presence of 500 /SM-Ca2" and (c) in the presence of 500 /tM-Ca2" followed by 15 We wondered whether the effects of calmedin merely reflected a Ca2+-sensitive protease. In preliminary experiments we showed that the ability of calmedin to confer Ca2+-sensitivity to the InsP3 receptor was completely reversed by 1 mM-EDTA, ruling out proteolysis [14] . To characterize the reversibility of calmedin action, we examined the time course of the effect of EDTA (Fig.  1 (Fig. 2a) servations [14] experiments to ensure saturation, because we found that subtle pipetting errors could lead to large variations in free Ca2" concentrations in EDTA buffer as measured by a Ca2" electrode.
[3H]InsP3 binding to detergent-solubilized cerebellar membranes is inhibited potently by Ca2". The effect of Ca2" is lost after purification of the receptor on a heparin-agarose column, to which the InsP3 receptor protein adheres [14] . Calmedin activity does not adhere to the heparin column, and can be routinely assessed in portions of the heparin flow-through. The ability of calmedin to confer Ca2" inhibition was concentrationdependent (Fig. 2b) 400 column (Fig. 3) . Calmedin activity emerged as a relatively sharp peak with an apparent Mr greater than that of alcohol dehydrogenase (80000) but less than that of thyroglobulin (700000). We estimate the native Mr of calmedin to be about 300000. This value is likely to be an overestimate, owing to the well-known increase in apparent Stokes radius of membrane proteins which bind Triton X-100. We assayed the ability of each of the fractions from the S-400 column to bind 45Ca2+, using Chelex columns to separate free 45Ca2+ from bound radioactivity. 45Ca2+ binding was low throughout most of the column and highest in the included fraction. There was no correlation between 45Ca2+ binding and calmedin activity (results not shown). Calmedin does not appear to be identical with either calmodulin or calcineurin, well-known Ca2+-binding proteins, because these proteins partition predominantly into the soluble fraction, unlike calmedin, which is membranous.
We also examined the chromatographic properties of calmedin with ion-exchange columns (results not shown). Calmedin was not retained by a DEAE-cellulose column at pH 7.7, in 0.1 M-NaCl. Calmedin was also not retained by a CM-cellulose column at pH 7.7 in the absence of NaCl. This suggests that calmedin is a neutral protein.
Calmedin activity was stable when frozen at -70°C for at least 4 Regional and species distribution of calmedin InsP3 receptor binding densities vary markedly throughout the brain, with much higher densities in the cerebellum than in any other brain region, and with very low values in peripheral tissues [13, 14] . To assess the regional distribution of calmedin activity, we added amounts of tissue protein from various rat brain areas equal to cerebellar protein content which was just sufficient to provide a near-maximal inhibition by Ca2" of InsP3 binding (Table 2 ; Fig. 2b ). The calmedin activities of the three brain regions and the spinal cord were closely similar. No region appeared to possess substantially less calmedin activity than the cerebellum. From our experimental design we cannot rule out the possibility that other regions might contain more calmedin activity than the cerebellum. Calmedin activity in the cerebellum, thalamus and cerebral cortex was completely reversed by a 10 min incubation with EDTA, whereas only 50 % reversal was obtained in the spinal cord.
In contrast with the robust calmedin activity ofcentralnervous-system areas, the five peripheral tissues assayed displayed very low calmedin activity.
DISCUSSION
The major finding of our study is that a membraneassociated protein of [16] , a Mr-21 000 calciprotein (KD = 1 /tM) isolated from bovine brain [17] , Ca2+-ATPase of the sarcoplasmic reticulum (KD = 300 nM) [18] and Ca2+/phospholipid-dependent protein kinase C [KD (in presence of diacylglycerol) = 100 nM] [3] . It is unlikely that calmedin is either glycerol-3-phosphate dehydrogenase or Ca2+-ATPase, since both of these are ubiquitous in peripheral tissue. The Mr-21 000 brain calciprotein and protein kinase C have different apparent Mr values from that of calmedin. InsP3 binding to receptors in peripheral tissues is not inhibited by Ca2" [8] [9] [10] [11] . The very low amounts of calmedin detected in peripheral tissues might account for the failure of peripheral InsP3 receptors to respond to Ca2".
